South Korea · Delayed Price · Currency is KRW Meta Biomed Statistics
Total Valuation
Meta Biomed has a market cap or net worth of KRW 115.54 billion. The enterprise value is 120.95 billion.
| Market Cap | 115.54B |
| Enterprise Value | 120.95B |
Important Dates
The next estimated earnings date is Friday, May 15, 2026.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Meta Biomed has 26.14 million shares outstanding. The number of shares has decreased by -7.40% in one year.
| Current Share Class | 26.14M |
| Shares Outstanding | 26.14M |
| Shares Change (YoY) | -7.40% |
| Shares Change (QoQ) | -4.77% |
| Owned by Insiders (%) | 22.44% |
| Owned by Institutions (%) | 5.82% |
| Float | 20.28M |
Valuation Ratios
The trailing PE ratio is 10.10 and the forward PE ratio is 7.14.
| PE Ratio | 10.10 |
| Forward PE | 7.14 |
| PS Ratio | 1.12 |
| PB Ratio | 0.93 |
| P/TBV Ratio | 0.95 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 5.83 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.42, with an EV/FCF ratio of -256.71.
| EV / Earnings | 11.01 |
| EV / Sales | 1.17 |
| EV / EBITDA | 4.42 |
| EV / EBIT | 5.54 |
| EV / FCF | -256.71 |
Financial Position
The company has a current ratio of 1.39, with a Debt / Equity ratio of 0.34.
| Current Ratio | 1.39 |
| Quick Ratio | 0.97 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | 1.60 |
| Debt / FCF | -90.67 |
| Interest Coverage | 7.45 |
Financial Efficiency
Return on equity (ROE) is 9.75% and return on invested capital (ROIC) is 14.38%.
| Return on Equity (ROE) | 9.75% |
| Return on Assets (ROA) | 7.28% |
| Return on Invested Capital (ROIC) | 14.38% |
| Return on Capital Employed (ROCE) | 16.69% |
| Weighted Average Cost of Capital (WACC) | 7.54% |
| Revenue Per Employee | 337.55M |
| Profits Per Employee | 36.03M |
| Employee Count | 305 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 2.35 |
Taxes
In the past 12 months, Meta Biomed has paid 1.82 billion in taxes.
| Income Tax | 1.82B |
| Effective Tax Rate | 14.47% |
Stock Price Statistics
The stock price has decreased by -6.16% in the last 52 weeks. The beta is 0.72, so Meta Biomed's price volatility has been lower than the market average.
| Beta (5Y) | 0.72 |
| 52-Week Price Change | -6.16% |
| 50-Day Moving Average | 4,550.70 |
| 200-Day Moving Average | 5,214.50 |
| Relative Strength Index (RSI) | 46.97 |
| Average Volume (20 Days) | 131,219 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Meta Biomed had revenue of KRW 102.95 billion and earned 10.99 billion in profits. Earnings per share was 437.65.
| Revenue | 102.95B |
| Gross Profit | 53.59B |
| Operating Income | 21.19B |
| Pretax Income | 12.59B |
| Net Income | 10.99B |
| EBITDA | 26.69B |
| EBIT | 21.19B |
| Earnings Per Share (EPS) | 437.65 |
Balance Sheet
The company has 37.86 billion in cash and 42.72 billion in debt, with a net cash position of -4.86 billion or -185.81 per share.
| Cash & Cash Equivalents | 37.86B |
| Total Debt | 42.72B |
| Net Cash | -4.86B |
| Net Cash Per Share | -185.81 |
| Equity (Book Value) | 124.87B |
| Book Value Per Share | 4,593.59 |
| Working Capital | 23.18B |
Cash Flow
In the last 12 months, operating cash flow was 19.83 billion and capital expenditures -20.30 billion, giving a free cash flow of -471.17 million.
| Operating Cash Flow | 19.83B |
| Capital Expenditures | -20.30B |
| Depreciation & Amortization | 5.50B |
| Net Borrowing | -6.96B |
| Free Cash Flow | -471.17M |
| FCF Per Share | -18.02 |
Margins
Gross margin is 52.06%, with operating and profit margins of 20.59% and 10.67%.
| Gross Margin | 52.06% |
| Operating Margin | 20.59% |
| Pretax Margin | 12.23% |
| Profit Margin | 10.67% |
| EBITDA Margin | 25.93% |
| EBIT Margin | 20.59% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 105.00, which amounts to a dividend yield of 2.31%.
| Dividend Per Share | 105.00 |
| Dividend Yield | 2.31% |
| Dividend Growth (YoY) | 250.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 6.23% |
| Buyback Yield | 7.40% |
| Shareholder Yield | 9.73% |
| Earnings Yield | 9.51% |
| FCF Yield | -0.41% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 23, 2010. It was a forward split with a ratio of 2.
| Last Split Date | Apr 23, 2010 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Meta Biomed has an Altman Z-Score of 2.78 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.78 |
| Piotroski F-Score | 7 |